Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain-Reference-Cited by-同舟云学术

Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain

Published:2023-06-01 Issue:6 Volume:80 Page:542
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Abdelhak Ahmed¹,Kuhle Jens²³,Green Ari J.¹

Affiliation:

1. Weill Institute for Neurosciences, Department of Neurology, University of California at San Francisco

2. Department of Neurology, University of Basel, Basel, Switzerland

3. Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, Basel, Switzerland

Abstract

This Viewpoint describes the benefits and limitations of using neurofilament light chain (NfL) as a marker of real-time disease activity and treatment response in multiple sclerosis.

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2802789/jamaneurology_abdelhak_2023_vp_230003_1686342373.3235.pdf

Reference7 articles.

1. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.;Benkert;Lancet Neurol,2022

2. A kinetic model for blood biomarker levels after mild traumatic brain injury.;Azizi;Front Neurol,2021

3. Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology.;Berry;Alzheimers Dement (Amst),2022

4. Contributors to serum NfL levels in people without neurologic disease.;Fitzgerald;Ann Neurol,2022

5. Associations of sNfL with clinico-radiological measures in a large MS population.;Sotirchos;Ann Clin Transl Neurol,2023

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-07

2. Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis;Pharmacological Reviews;2024-05-06

3. Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review;International Journal of Molecular Sciences;2024-03-28

4. Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls;Molecular Psychiatry;2024-03-19

5. NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study;Journal of Neurology, Neurosurgery & Psychiatry;2024-01-19